NOTICE TO CONVENE THE ANNUAL GENERAL MEETING

DANISH BIO - DANSK BIOTEK

(CVR no. 28 43 65 72)

Notice is hereby given to the Annual General Meeting of DANISH BIO - DANSK BIOTEK to be held on

Thursday, 21 May 2026, at 14:00 (CEST)

at Plesner Advokatpartnerselskab, Amerika Plads 37, 2100 Copenhagen Ø

The agenda is as follows:

a) Election of Chairman of the Annual General Meeting

b) Chairman of the Board's statement

c) Approval of financial results for 2025

d) Determination of membership fees for 2027

e) Election of Chairman of the Board

f) Election of Members of the Board

g) Election of Auditor

h) Discussion of proposals

i) Any other business

Re a) - Election of Chairman of the Annual General Meeting

The Board proposes election of a representative from Plesner Advokatpartnerselskab as Chairman of the Annual General Meeting.

Re b) - Chairman of the Board's statement

Chairman of the Board, Hans Schambye, makes his statement regarding the previous year.

Re c) - Approval of financial results for 2025

The Board proposes that the Annual Report with the auditor's report for 2025 be approved.

Re d) - Determination of membership fees for 2027

The Board proposes that the membership fees for 2027 shall remain unchanged compared to 2026.

Re e) - Election of Chairman of the Board

The Chairman of the Board is elected for a two-year term and may be re-elected.

Hans Schambye was elected in 2025 and continues as Chairman of the Board (during the term 2025-2027), and therefore no proposal has been made under this agenda item.

Re f) - Election of Members of the Board

The Members of the Board are each elected for a two-year term and may be re-elected.

The Board proposes re-election of the following Members, who stand for election:

- Jørgen Godt Olsen, Executive Vice President, Niels Clauson-Kaas (2026-2028)
- Thomas Kongstad Petersen, Chief Operating Officer, NMD Pharma (2026-2028)

The following Members of the Board continue:

- Hans Schambye, CEO, Boost Pharma ApS (Chairman) (2025-2027)
- Henrik Blou, CEO, Gubra (2025-2027)
- Lone Dybdal Nilsson, Vice President, Vice President, Applied Research, HHC Industrial, Novonesis (2025-2027)
- Søren Møller, Managing Partner, Novo Holdings A/S (2025-2027)
- Lasse Nørregaard, Chief Business Officer, XY Therapeutics, Loma Therapeutics, Probmet Therapeutics (2025-2027)

Maj-Brit Zocca does not stand for re-election.

Re g) - Election of Auditor

The Board proposes re-election of EY Godkendt Revisionspartnerselskab, CVR no. 30 70 02 28, as the auditor of DANISH BIO - DANSK BIOTEK.

Re h) - Discussion of proposals

No proposals have been received under this agenda item.

Re i) - Any other business

Any other business.

- 0 -

Resolution requirements

The proposals set out in items a)-g) of the agenda must be adopted by a simple majority of votes.

Practical information

To ensure a smooth course of events at the Annual General Meeting, we encourage the Members of DANISH BIO - DANSK BIOTEK to give proxy to the Chairman of the Annual General Meeting to vote on their behalf at the Annual General Meeting (power of attorney is attached to this notice). A scanned copy of the completed and signed power of attorney must be sent by e-mail to: ps@danskbiotek.dk no later than on Tuesday, 20 May 2026, at 10:00 (CEST).

Further, we encourage the Members of DANISH BIO - DANSK BIOTEK to submit any questions well in advance of the Annual General Meeting.

- 0 -

Date: 6 May 2026

Kind regards

The Board of DANISH BIO - DANSK BIOTEK